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Aberrant gene methylation is often seen in thyroid cancer, a common endocrine malig-
nancy.Tobacco smoking has been shown to be associated with aberrant gene methylation
in several cancers, but its relationship with gene methylation in thyroid cancer has not
been examined. In the present study, we investigated the relationship between smok-
ing of patients and aberrant methylation of tumor suppressor genes for TIMP3, SLC5A8,
death-associated protein kinase, and retinoic acid receptor β2 (RARβ2) in papillary thyroid
cancer (PTC), the most common type of thyroid cancer. The promoter methylation sta-
tus of these genes was analyzed using quantitative real-time methylation-speciﬁc PCR on
bisulﬁte-treated genomic DNA isolated from tumor tissues and correlated with smoking
history of the patients. Among the four genes, methylation of the RARβ2 gene was sig-
niﬁcantly associated with smoking and other three genes showed a trend of association.
Speciﬁcally, among the 138 patients investigated, 13/42 (31.0%) ever smokers vs. 10/96
(10.4%) never smokers harbored methylation of the RARβ2 gene (P = 0.003). This asso-
ciation was highly signiﬁcant also in the subset of conventional variant PTC (P = 0.005)
and marginally signiﬁcant in follicular variant PTC (P = 0.06). The results demonstrate that
smoking-associated aberrant methylation of the RARβ2 gene is a speciﬁc molecular event
that may represent an important mechanism in thyroid tumorigenesis in smokers.
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INTRODUCTION
Thyroid cancer is a common endocrine malignancy with a rapidly
rising incidence in recent decades and at least 458,403 patientswith
thyroid cancer are currently living in the United States (Howlader
et al., 2011). The most common histological type of this cancer
is papillary thyroid cancer (PTC), which accounts for >80% of
all thyroid malignancies (Hundahl et al., 1998; Howlader et al.,
2011). PTC can be further divided into several subtypes, includ-
ing mainly, in the order of decreasing prevalences, conventional,
follicular variant and tall-cell PTC.Among themolecular derange-
ments that drive thyroid tumorigenesis are epigenetic alterations,
particularly aberrant genemethylation (Xing, 2007). Genemethy-
lation is the covalent addition of amethyl group to the ﬁfth carbon
position of the cytosine residue in a CpG dinucleotide, which is
usually associated with gene silencing and is a common mecha-
nism for functional loss of key genes in human cancers (Esteller,
2008). Aberrant gene methylation in thyroid tumorigenesis often
involves major tumor suppressor genes, such as those for the
tissue inhibitor of metalloproteinase-3 (TIMP3), SLC5A8, death-
associated protein kinase (DAPK), and retinoic acid receptor β2
(RARβ2), particularly in PTC (Hoque et al., 2005; Hu et al., 2006).
The tumor suppressor functions of these genes have been well
characterized and they are frequently methylated in cancers. For
example, the anti-tumor role of the RARβ2 gene, which is often
silenced by aberrant methylation in cancers, is mediated through
inhibition of cancer cell proliferation and metastasis and induc-
tion of apoptosis (Raffo et al., 2000; Widschwendter et al., 2001;
Treuting et al., 2002). Conversely, re-expression of RARβ2 is asso-
ciated with signiﬁcant reduction of cell growth in thyroid cancer
cells (Miasaki et al., 2008).
Few environmental risk factors for thyroid cancer are known.
Ionizing radiation exposure, the best-established risk factor for
thyroid cancer, can induce RET/PTC rearrangements and conse-
quent development of PTC, particularly in the pediatric popula-
tion (Nikiforov, 2006). No environmental risk factor is known to
cause epigenetic alterations in thyroid cancer. Smoking is a well
known risk factor in many cancers. Smoking has also been widely
shown to be a signiﬁcant risk factor for the development of thyroid
nodule/goiter, particularly in women (Lio et al., 1989; Ericsson
and Lindgarde, 1991; Galanti et al., 2005). Thyroid nodule/goiter
is, in turn, a strong risk factor for thyroid cancer (Preston-Martin
et al., 1993; Franceschi et al., 1999). Although some studies did not
show an increased risk associated with smoking for thyroid cancer
(Ron et al., 1987;Kreiger andParkes, 2000; Bandurska-Stankiewicz
et al., 2011),others did show an association of smokingwith occur-
rence of thyroid cancer (Sokic et al., 1994). Interestingly, smoking
has been found to be associated with aberrant gene methyla-
tion in some cancers, such as the RARβ2 gene methylation in
human lung cancer (Tomizawa et al., 2004) and animal lung can-
cer models (Vuillemenot et al., 2004). The effect of smoking on
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gene methylation has not been explored in thyroid cancer. In the
present study, we investigated the relationship of smoking with
methylation of several major tumor suppressor genes in PTC.
MATERIALS AND METHODS
PATIENTS
With Institutional Review Board approval and, where required,
informed patient consent, we included 138 patients (99 female
and 39male, age 15–85 years),whowere operated for PTCbetween
1990 and 2006 and had recorded history of smoking status, in this
study. These included 96 patients as never smokers and 42 patients
as ever smokers. The latter included current and former smokers.
The smoking history of a patient was obtained through a retro-
spective review of the patient’s records. Smoking histories of the
ever smokers varied from 2 to 35 pack years of cigarette smok-
ing. A pack-year is deﬁned as equivalent to smoking one pack of
cigarettes daily for a period of 1 year.
METHYLATION ANALYSIS
Parafﬁn-embedded PTC tumors were microdissected and
processed and genomic DNA was isolated as described previously
(Hu et al., 2006). Bisulﬁte-treated DNA was subjected to methy-
lation analysis for the promoters of the tumor suppressor genes
TIMP3, SLC5A8, DAPK, and RARβ2 using real-time quantitative
methylation-speciﬁc PCR. The primers for these genes and PCR
reaction conditions were as described previously (Hu et al., 2006).
Any detectable level of methylation for the indicated genes deﬁned
as a positive methylation result and zero value on the current
detection system was deﬁned as a negative methylation result.
STATISTICAL ANALYSIS
Categorical data were summarized with frequencies and percent-
ages, and continuous data with medians and ranges. Age and
gender distribution were analyzed utilizing Mann–Whitney rank
sum test andFisher’s exact test, respectively. Smoking status groups
were compared using Fisher’s exact test for categorical data, and
the non-parametric Wilcoxon rank sum test for continuous mea-
sures. All reported P values are two-sided. A P-value of <0.05 was
considered to be statistically signiﬁcant. Analysis was performed
using SAS version 9.1.3 software (SAS Institute Inc., Cary, NC,
USA).
RESULTS
We analyzed 138 PTC for the methylation status of the tumor sup-
pressor genes TIMP3, SLC5A8, DAPK, and RARβ2. These genes
were chosen for analysis because they are important human tumor
suppressor genes and their methylation was frequently found in
thyroid cancer (Hoque et al., 2005;Hu et al., 2006).Overall,methy-
lation of these genes were detected in 67 (48.5%), 36 (26.1%),
40 (29.0%), and 23 (16.7%) of the 138 cases, respectively. Age
and gender were potential confounding variables that could affect
gene methylation. As shown in Table 1, except for the age of the
DAPK methylation-positive patients that was signiﬁcantly older
in the ever-smoker group than the never-smoker group, there was
no signiﬁcant difference in the age of the methylation-positive
patients for the remaining three genes between the ever-smoker
and never-smoker groups. Similarly, as shown in Table 2, there was
Table 1 | Comparison of mean ages of methylation-positive patients
for the indicated genes between the ever-smoker and never-smoker
groups.
Genes Mean age P value
Ever smoker Never smoker
RARβ2 53.4±17.6 48.7±18.2 0.456
DAPK 54.9±12.4 44.9±14.9 0.037
TIMP3 54.2±13.4 47.1±15.9 0.097
SLC5A8 55.4±13.7 45.3±14.9 0.064
Table 2 | Gender distribution of methylation-positive patients for the
indicated genes [n (%)] (%=n/N ).
Genes Female Male P value
n=99 n=39
RARβ2 15 (15) 8 (20) 0.45
DAPK 30 (30) 10 (26) 0.68
TIMP3 50 (50) 17 (44) 0.57
SLC5A8 30 (30) 6 (15) 0.09
no signiﬁcant difference in gender distribution of methylation-
positive patients for the four genes examined in the present study.
Also, smoking did not affect the relationship of gene methylation
with tumor size and other tumor characteristics (data not shown).
We next analyzed the relationship of gene methylation in PTC
with cigarette smoking history in 138 patients. As summarized in
Table 3 and Figure 1, among the four tumor suppressor genes ana-
lyzed,methylation of the RARβ2 gene was signiﬁcantly associated
with a history of smoking. Speciﬁcally, 13/42 (31.0%) ever smok-
ers vs. 10/96 (10.4%) never smokers harbored methylation in the
promoter of the RARβ2 gene (P = 0.003). Although there was no
statistically signiﬁcant difference in themethylation of theTIMP3,
SLC5A8, and DAPK genes between the never and ever smokers,
there was a tendency of higher prevalences of methylation in these
genes in the smokers (Figure 1; Table 3).
The 138 cases of PTC included 72 conventional PTC, 51 fol-
licular variant PTC, and 15 tall-cell PTC. We also analyzed the
relationship of smoking with gene methylation in each of the sub-
type groups of PTC. As shown in Table 3, similar to the results on
the overall analysis of all the cases of PTC,RARβ2 methylationwas
signiﬁcantly associated with smoking [8/17 (47%) of ever smok-
ers vs. 7/55 (13%) of never smokers, P = 0.005] in conventional
PTC. In the smaller number of cases of follicular variant PTC,
marginally signiﬁcant association of smokingwithRARβ2 methy-
lationwas demonstrated (P = 0.06). This relationshipwasnot seen
in patients with tall-cell PTC, probably due to the small num-
ber of cases. A trend of association of smoking with the TIMP3,
SLC5A8, andDAPK methylationwas observed in these subtypes of
PTC. The average methylation levels for each gene in the ever and
never smokers were not signiﬁcantly different (Table 4). However,
this result was likely limited by the inability of the methylation
PCR approach used in the present study to accurately provide
quantitative measurements.
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Table 3 | Relationship of methylation of the RARβ2, DAPK,TIMP3, and
SLC5A78 genes in papillary thyroid cancer (PTC) with smoking of
patients [n (%)].
Tumors Genes Ever smoker Never smoker P value
All PTC n 42 96
RARβ2 13 (31.0) 10 (10.4) 0.003
DAPK 15 (35.7) 25 (26.0) 0.25
TIMP3 23 (54.8) 44 (45.8) 0.33
SLC5A8 14 (33.3) 22 (22.9) 0.20
Conventional PTC n 17 55
RARβ2 8 (47) 7 (13) 0.005
DAPK 8 (47) 18 (33) 0.28
TIMP3 12 (71) 30 (55) 0.24
SLC5A8 8 (47) 15 (27) 0.13
Follicular variant PTC n 19 32
RARβ2 4 (21) 1 (3) 0.06
DAPK 3 (16) 2 (6) 0.35
TIMP3 7 (37) 7 (22) 0.25
SLC5A8 2 (11) 2 (6) 0.62
Tall-cell PTC n 6 9
RARβ2 1 (17) 2 (22) 1.0
DAPK 4 (67) 5 (56) 1.0
TIMP3 4 (67) 7 (78) 1.0
SLC5A8 4 (67) 5 (56) 1.0
FIGURE 1 | Aberrant gene methylation in papillary thyroid cancer in
ever and never smokers. Shown on y -axis is the methylation
rate – percentage of the methylation-positive cases (%) – for each of the
four genes indicated on the x -axis. *The methylation rate of the RARβ2
gene is signiﬁcantly higher (P =0.003) in the ever smoker group than the
never smoker group. The methylation rate for the remaining three genes
shows a higher trend for ever smokers but does not reach statistical
signiﬁcance.
DISCUSSION
Tobacco smoking has long been known to be a signiﬁcant risk fac-
tor for human cancers. This has prompted numerous studies on its
role in molecular derangements in cancers, including genetic and
epigenetic alterations, such as aberrant gene methylation. Smok-
ing has also been shown to be associated with the development
Table 4 | Comparison of methylation levels for the indicated genes in
papillary thyroid cancer between ever and never smokers.
Genes Mean methylation levels P value
Ever smoker Never smoker
RARβ2 0.374±0.73 3.205±8.47 0.067
DAPK 8.565±18.62 3.428±5.82 0.252
TIMP3 5.254±4.59 5.375±7.71 0.222
SLC5A8 31.145±51.26 26.219±39.15 0.783
of thyroid nodules in many studies (Lio et al., 1989; Ericsson
and Lindgarde, 1991; Galanti et al., 2005), a strong risk factor
for thyroid cancer (Preston-Martin et al., 1993; Franceschi et al.,
1999), and occurrence of thyroid cancer in some studies (Sokic
et al., 1994). However, little is known about molecular derange-
ments associated with smoking in thyroid cancer. In the present
study, we for the ﬁrst time investigated the relationship between
patient smoking and aberrant gene methylation in PTC, the most
common type of thyroid cancer. We found a signiﬁcant associ-
ation of smoking with methylation of the RARβ2 gene in PTC,
both in overall PTC and in its major subtypes. This association
represented a speciﬁc epigenetic event in PTC as the association
of smoking with the methylation of other genes (TIMP3, SLC5A8,
and DAPK ) was not signiﬁcant. Some of the relationship pat-
terns of smoking with methylation of tumor suppressor genes in
PTC observed in the present study were similar to the ﬁndings in
other cancers. For example, as in the present study which failed to
show a signiﬁcant association of DAPK methylation with smok-
ing in PTC, such an association was also not found in non-small
lung cancer patients (Liu et al., 2007). Similar to our ﬁndings
in PTC, previous studies demonstrated a signiﬁcant association
of smoking with RARβ2 methylation in lung cancers in humans
(Tomizawa et al., 2004) and in animal models (Vuillemenot et al.,
2004). Interestingly, even in normal non-cancerous epithelium of
upper aerodigestive tract, methylation of the RARβ2 gene and
other genes was more frequently seen in smokers (Zochbauer-
Muller et al., 2003), supporting a direct effect of smoking on gene
aberrant methylation. Frequent methylation of the RARβ2 gene
has also been recently detected in laryngeal squamous cell carcino-
mas (Paluszczak et al., 2011), a malignancy often associated with
smoking.
We previously demonstrated that methylation of the tumor
suppressor gene RARβ2 was associated with its silencing and,
conversely, un-methylation was associated with expression of this
gene in thyroid cancer cells (Hu et al., 2006). Re-expression of
RARβ2 using demethylating agent 5-aza-2′-deoxycytidine caused
a signiﬁcant inhibition of thyroid cancer cell growth (Miasaki
et al., 2008). The association of smoking with RARβ2 methyla-
tion in PTC suggests that this gene may more commonly loose
function in PTC of smokers. RARβ2 is a major type of retinoic
acid (RA) receptors, which are transcription factors that bind
with the biologically active metabolites of vitamin A to reg-
ulate cell growth and proliferation (Pfahl and Chytil, 1996).
Therapeutic potential of vitamin A and retinoic acid has been
demonstrated in various human cancers. RA has been shown to
www.frontiersin.org December 2011 | Volume 2 | Article 99 | 3
Kiseljak-Vassiliades and Xing Smoking and gene methylation in thyroid cancer
be able to re-differentiate thyroid cancer cell lines and increase
radioiodine uptake in some patients who lost radioiodine avidity
(Haugen et al., 2004; Coelho et al., 2005). However, the over-
all treatment efﬁcacy is poor. One cause for the failure of RA
therapy for thyroid cancer is the loss of RA receptor expres-
sion in this cancer. In vitro studies showed that RA could only
inhibit the growth of thyroid cancer cell lines that expressed
RARβ and some other RA receptors (Haugen et al., 2004; Eli-
sei et al., 2005). Expression of RA receptors is often decreased
or lost in thyroid cancers, particularly in PTC in which expres-
sion of the RARβ gene was most frequently decreased or silenced
(Tang et al., 2003; Elisei et al., 2005). Our previous demonstration
of aberrant RARβ2 gene methylation in thyroid cancer provided
a molecular explanation (Hoque et al., 2005; Hu et al., 2006).
Given these data and the results in the present study, it is clear
that aberrant methylation of RA receptor genes is an impor-
tant molecular event in PTC associated with smoking. How this
aberrant methylation of RARβ2 gene speciﬁcally contributes to
the tumorigenesis of PTC in smokers warrants further studies to
elucidate.
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